Alzheimer's Disease is a neurodegenerative disease of unknown etiology that is eventually fatal. It is a brain disease that slowly destroys brain cells - and there is no cure available yet. Alzheimer's Disease (AD) is the most common form of senile dementia accounting for about 70% of all cases. The estimated number of affected individuals is about 3m in Europe, 3m in the US and 1.5m in Japan. While AD shortens the lives of those affected, its greatest impact is upon the quality of life, both of those living with dementia, and their family and caregivers. The development of a disease-modifying therapy for AD is therefore a high unmet medical need.
AmypoPharma Srl has been founded in 2015 on the basis of its proprietary nano-carrier technology named Amyposomes®.
The company’s mission is to establish Amyposomes® as a novel brand of functionalized nanoliposomes to target Alzheimer Disease (AD) and potentially other diseases where so far no efficient cure for patients is available on the market.
Breslin provides strategic advice for private equity and secondary transactions as well as for corporate development and corporate finance. Clients include Private Equity, Venture Capital, Global Financial Service Providers and companies active in the Pharmaceutical, Biotechnology, Medical Device and Diagnostic market segments of the Life Sciences sector.
The Market for Alzheimer’s Disease
According to the 2015 World Alzheimer Report on Dementia, including Alzheimer’s disease and other causes, AD is one of the biggest global public health and social care challenges facing people today and in the future. It is estimated that there will be 9.9 million new cases of dementia in 2015, or one every 3 seconds. 49% of these will arise in Asia, 25% in Europe, 17% in the Americas and 8% in Africa. Alzheimer’s Disease accounts for the majority of these incidences.